Indonesia will require exports of key commodities to pass through a state-appointed enterprise in a sweeping effort to curb revenue leaks, tighten oversight of natural resources and keep more foreign exchange earnings at home. The policy, announced by President Prabowo Subianto in a rare address to parliament on Wednesday, would apply to palm oil, coal and ferroalloys – three major export earners ...
Indonesia will require exports of key commodities to pass through a state-appointed enterprise in a sweeping effort to curb revenue leaks, tighten oversight of natural resources and keep more foreign exchange earnings at home. The policy, announced by President Prabowo Subianto in a rare address to parliament on Wednesday, would apply to palm oil, coal and ferroalloys – three major export earners for Southeast Asia’s largest economy. Under the new regulation, producers would have to sell their commodities to the new state-run agency, which would then transact with overseas buyers , effectively ending direct international sales by private companies. Advertisement Prabowo framed the move as a necessary step to tackle under-invoicing, transfer pricing and other practices he said had drained money from Indonesia’s economy and weakened the state’s ability to fund public services. But the plan has also triggered warnings from economists, farmers and industry groups, who say the shift could create a state monopoly, disrupt existing contracts and complicate Indonesia’s access to global markets. Advertisement “Over the past 22 years, Indonesia recorded a trade surplus of US$436 billion, but US$343 billion flowed out of the country. This is why teachers’ salaries remain low, why civil servants struggle, and why our budget often feels insufficient,” Prabowo said. “One of the major causes is under-invoicing, a form of fraud. Some exporters deliberately report lower export values than the actual transaction value, often through overseas shell companies they control. This practice occurs in palm oil, mining, and many other commodities.”
Beijing has accused Taiwanese leader William Lai Ching-te of “destroying cross-strait peace” shortly after he gave a speech to mark his second anniversary in power in the wake of Donald Trump’s remarks on Taiwan independence. The State Council’s Taiwan Affairs Office (TAO) said on Tuesday that Lai’s anniversary speech and his subsequent remarks to reporters were filled with “lies and deception, ho...
Beijing has accused Taiwanese leader William Lai Ching-te of “destroying cross-strait peace” shortly after he gave a speech to mark his second anniversary in power in the wake of Donald Trump’s remarks on Taiwan independence. The State Council’s Taiwan Affairs Office (TAO) said on Tuesday that Lai’s anniversary speech and his subsequent remarks to reporters were filled with “lies and deception, hostility and confrontation”. Spokesman Chen Binhua said Lai had “stubbornly adhered to the erroneous stance of Taiwan independence”, and promoted what Beijing called the fallacies of “sovereign independence” and “mutual non-subordination”. Advertisement Lai had once again proven himself to be an outright “destroyer of cross-strait peace” and a “maker of Taiwan Strait crises”, Chen said. The tough talk came after US President Donald Trump said last week he did not support Taiwan independence and was “not looking to have somebody go independent”, remarks that reignited debate on the island over whether Taipei could be left out in the cold in a broader US-China bargain. Advertisement Lai’s televised speech appeared to be aimed at addressing those concerns by portraying his administration as firm but measured in defending the island against pressure from Beijing.
A professor of psychobiology argues that art – from painting to theatre – has a measurable impact on our health After Daisy Fancourt’s daughter Daphne was born prematurely, she was confined to an incubator, fighting for her life against a series of infections. Unable to touch her baby or even properly enter the room, Fancourt kept vigil just inside the door, dressed head to toe in PPE, singing lul...
A professor of psychobiology argues that art – from painting to theatre – has a measurable impact on our health After Daisy Fancourt’s daughter Daphne was born prematurely, she was confined to an incubator, fighting for her life against a series of infections. Unable to touch her baby or even properly enter the room, Fancourt kept vigil just inside the door, dressed head to toe in PPE, singing lullabies over the whir of instruments and alarms. The songs calmed her, and may have been crucial for Daphne too. Studies show that singing to babies in intensive care reduces their heart rate, improves their breathing, and encourages them to feed. It was a moment when Fancourt’s professional and personal lives collided. A professor of psychobiology and epidemiology at University College London, she researches how social connections and behaviours affect our health. In Art Cure, her first book for a popular audience, she aims to make a scientific case that the arts – from playing music to theatre-going to painting – aren’t a merely aesthetic aspect of life. Instead, they are deeply entwined with our mental and physical wellbeing at every level – from the workings of our cells and molecules to cognition, memory and mood. In an era of shrinking arts funding and overstretched healthcare systems, her message is urgent. But how to compile rigorous evidence for something as holistic, indefinable – and, perhaps, resolutely unscientific – as art? Continue reading...
A New York exhibit of more than 3,000 volumes bills itself as ‘an exercise in radical transparency’ – and a bid for attention This February, a story broke that seemed like it might finally be the one . Reporters at NPR had noticed that there were pages missing from the enormous tranche of Epstein files released by the Department of Justice. Further reporting revealed that the files in question wer...
A New York exhibit of more than 3,000 volumes bills itself as ‘an exercise in radical transparency’ – and a bid for attention This February, a story broke that seemed like it might finally be the one . Reporters at NPR had noticed that there were pages missing from the enormous tranche of Epstein files released by the Department of Justice. Further reporting revealed that the files in question were 2019 FBI interviews with a woman who claimed to have been sexually abused by Jeffrey Epstein and Donald Trump when she was a minor. The justice department had no good explanation for why the documents had been withheld. Trump issued blanket denials. It was all starting to feel like a good old-fashioned something-gate, the kind of scandal that might even bring down a presidency. But then, as with so many other stories in the era of Trump, its spark was subsumed by a new fire. On 28 February, Trump launched an unprovoked and likely illegal war against Iran, and the Epstein files were once again pushed off the front pages. Continue reading...
As one of Britain’s leading TV sports presenters for the best part of three decades, Sue Barker has always been more comfortable asking questions than answering them. Many who watched her relaxed, confident style as she presented coverage of Wimbledon from 1993 to 2022 probably did not know she was once a tennis player herself. Fewer still would have known that Barker is a grand slam champion. Her...
As one of Britain’s leading TV sports presenters for the best part of three decades, Sue Barker has always been more comfortable asking questions than answering them. Many who watched her relaxed, confident style as she presented coverage of Wimbledon from 1993 to 2022 probably did not know she was once a tennis player herself. Fewer still would have known that Barker is a grand slam champion. Her finest hour came at Roland Garros in 1976, when she won her first and only slam title, beating the Czech Renata Tomanova in three sets. This year’s event, which begins on Sunday, marks the 50th anniversary of Barker’s win. Following in the footsteps of Christine Truman, who won in 1959, and Ann Jones, who did it twice, in 1961 and 1966, Barker is the last British player, man or woman, to triumph in Paris. It remains one of the finest achievements in British tennis, and has a claim to be one of the most underrated in British sport. It does not help that the 1976 final was not shown live on television due, reportedly, to a strike by French camera technicians. It is also, no doubt, because of what happened at Wimbledon the following year, when Virginia Wade won the title most coveted by British players. Barker was upset by the Dutchwoman, Betty Stöve, in the semi-finals, a loss that hurt so much she could not bring herself to watch the final. Instead she went out and spent a good chunk of her £3,500 prize money on jewellery. View image in fullscreen Sue Barker spent a large chunk of her £3,500 prize money on jewellery after reaching the 1977 Wimbledon semi-finals. Photograph: Colorsport/Shutterstock Barker politely declined an interview request to mark the anniversary of her win in Paris, not wanting to look back too much. “It’s funny how some people look at their losses,” the former British No 1 Jo Durie says. “I know she was really disappointed in 1977 when she knew she could beat Virginia [but lost to Stöve].” Durie, who is four years younger than Barker, feels she should ...
Almost 50 years after he first got his hands on a computer, the Oxford professor still believes in the power of technology. Can his beloved game theory explain why Silicon Valley’s entrepreneurs consistently misuse it? Michael Wooldridge is like the teacher you wish you’d had: approachable, able to explain difficult things in simple terms, neither dauntingly highbrow nor off-puttingly cool, and ge...
Almost 50 years after he first got his hands on a computer, the Oxford professor still believes in the power of technology. Can his beloved game theory explain why Silicon Valley’s entrepreneurs consistently misuse it? Michael Wooldridge is like the teacher you wish you’d had: approachable, able to explain difficult things in simple terms, neither dauntingly highbrow nor off-puttingly cool, and genuinely enthusiastic about what he does. “I love it when you see the light go on in somebody, when they understand something that they didn’t understand before,” he says. “I find that incredibly gratifying.” He comes across a regular sort of guy, which, as an Oxford professor with more than 500 scientific articles and 10 books to his name, he clearly isn’t. Typically, his favourite work is his contribution to Ladybird’s Expert Books – an update of the classic children’s series – on artificial intelligence . “I’m very proud of this,” he says, as he hands me a copy from his bookshelf. We’re in his study in the University of Oxford’s somewhat municipal computing department on a sunny spring day. Maybe it’s the campus setting, but our discussion almost takes the form of a seminar. Continue reading...
Now the secret is out it is possible to look at Enzo Maresca’s incendiary remarks about his “worst 48 hours” at Chelsea through a different lens. Change is coming at Manchester City, who are preparing for Pep Guardiola’s departure at the end of the season, and it does not require much reading between the lines to work out their decision to pass the crown to Maresca was made a long time ago. There ...
Now the secret is out it is possible to look at Enzo Maresca’s incendiary remarks about his “worst 48 hours” at Chelsea through a different lens. Change is coming at Manchester City, who are preparing for Pep Guardiola’s departure at the end of the season, and it does not require much reading between the lines to work out their decision to pass the crown to Maresca was made a long time ago. There never was a clear explanation from the Italian after he sat in front of the media after Chelsea’s unspectacular 2-0 win over Everton on 13 December and surprised the room by taking the extraordinary step of going to war with his employers. “Since I joined the club, the last 48 hours have been the worst because many people didn’t support us,” he said. “People didn’t support me and the team.” Which people? Maresca never said and Chelsea were perplexed. The situation deteriorated over the next fortnight and it was hard not to feel Maresca was behaving like a man who wanted to be sacked. Chelsea, though, refused to pull the trigger. It was only when Maresca went into the manager’s office at Stamford Bridge after a 2-2 draw with Bournemouth on 30 December and told his bosses he did not want to conduct his post-match duties that it became clear there was no putting the genie back in the bottle. Sources familiar with that episode say that was the moment Maresca in effect handed in his resignation. He was gone two days later, the club statement landing early on New Year’s Day. Chelsea, unsurprisingly, have not moved on from Maresca informing them he had twice spoken to City while under contract. This was not a fond farewell. Maresca walked away without his severance, with three and a half years on his deal. Sources close to the former Leicester manager have acknowledged Chelsea are entitled to demand a sizeable compensation package for City to acquire his services. There were claims of Maresca clashing with Chelsea’s medical department over how much certain players could be used an...
The robotics startup Figure AI has been livestreaming humanoid robots placing thousands of packages onto a conveyor belt for nearly a week—a spectacle that included a robot competing against a human intern at one point. The promotional robot demo has become a viral sensation among tech enthusiasts, spurring YouTube commenters to name the robots and the company rapidly rolling out related robot mer...
The robotics startup Figure AI has been livestreaming humanoid robots placing thousands of packages onto a conveyor belt for nearly a week—a spectacle that included a robot competing against a human intern at one point. The promotional robot demo has become a viral sensation among tech enthusiasts, spurring YouTube commenters to name the robots and the company rapidly rolling out related robot merchandise in response. Users on X have described the livestream in glowing terms such as “the greatest product demo since Steve Jobs’ ‘one more thing.’” But despite such sentiments, it’s worth bearing in mind that even the most impressive robot demos represent narrow windows for understanding real-world robot capabilities. Figure’s event began on May 13 as a planned eight-hour robot demonstration featuring the company’s latest Figure 03 robots. The chosen robotic task involved inspecting the barcodes on various small packages—including cardboard boxes and soft padded envelopes or bags—and then placing the packages on a conveyor belt with the barcodes facing downward. The demo would feature the robots performing the task autonomously without any human intervention, according to Figure CEO Brett Adcock. Read full article Comments
More on Target Target Q1 2026 Earnings Preview: Shares Could Pull Back After A Strong Run Target: Missing The Mark Target: My Target Price Justifies The Recent Rally, Pause For Now Target impresses in Q1 with sales gains across its key categories Target beats top-line and bottom-line estimates; updates FY26 outlook
More on Target Target Q1 2026 Earnings Preview: Shares Could Pull Back After A Strong Run Target: Missing The Mark Target: My Target Price Justifies The Recent Rally, Pause For Now Target impresses in Q1 with sales gains across its key categories Target beats top-line and bottom-line estimates; updates FY26 outlook
More on Target Target Q1 2026 Earnings Preview: Shares Could Pull Back After A Strong Run Target: Missing The Mark Target: My Target Price Justifies The Recent Rally, Pause For Now Target impresses in Q1 with sales gains across its key categories Target beats top-line and bottom-line estimates; updates FY26 outlook Editor's note: This story has been updated to reflect Target's revised FY26 EPS gui...
More on Target Target Q1 2026 Earnings Preview: Shares Could Pull Back After A Strong Run Target: Missing The Mark Target: My Target Price Justifies The Recent Rally, Pause For Now Target impresses in Q1 with sales gains across its key categories Target beats top-line and bottom-line estimates; updates FY26 outlook Editor's note: This story has been updated to reflect Target's revised FY26 EPS guidance midpoint.
Prospective buyers arrive during an open house in Rancho Cucamonga, California, US, on Saturday, May 9, 2026. Kyle Grillot | Bloomberg | Getty Images Mortgage rates continued to climb higher last week, dampening demand for loans from both current homeowners and potential home buyers. They also pushed consumers to riskier loans that offer lower rates. Total mortgage application volume dropped 2.3% ...
Prospective buyers arrive during an open house in Rancho Cucamonga, California, US, on Saturday, May 9, 2026. Kyle Grillot | Bloomberg | Getty Images Mortgage rates continued to climb higher last week, dampening demand for loans from both current homeowners and potential home buyers. They also pushed consumers to riskier loans that offer lower rates. Total mortgage application volume dropped 2.3% from the previous week, according to the Mortgage Bankers Association's seasonally adjusted index. The weekly average contract interest rate for 30-year fixed-rate mortgages with conforming loan balances, $832,750 or less, increased last week to 6.56% from 6.46%, with points decreasing to 0.60 from 0.63, including the origination fee, for loans with a 20% down payment. That is the highest rate in 7 weeks. "Ongoing concerns around inflation from higher fuel costs combined with rising concerns over global public debt pushed Treasury yields higher in the U.S. and abroad last week," said Joel Kan, an MBA economist in a release. The adjustable-rate mortgage (ARM) share of total applications rose to nearly 10%, the highest since October 2025. ARMs are considered riskier because their rates reset after a fixed period. The average rate on a 5-year ARM last week was 5.76%. Applications for a mortgage to purchase a home dropped 4% for the week and were just 8% higher than the same week one year ago. Last year at this time, mortgage rates were closer to 7%. Get Property Play directly to your inbox CNBC's Property Play with Diana Olick covers new and evolving opportunities for the real estate investor, delivered weekly to your inbox. Subscribe here to get access today . Applications to refinance a home loan fell 0.1% from the previous week and were 35% higher than the same week one year ago. "Overall applications were down to the lowest level in five weeks as purchase borrowers pulled back across conventional and government loan types," added Kan. Mortgage rates continued to climb this...
US mortgage rates increased last week to an almost two-month high, weighing on home purchase activity. The contract rate on a 30-year mortgage rose 10 basis points to 6.56% in the week ended May 15, according to Mortgage Bankers Association data released Wednesday, just shy of the 6.57% reading at the end of March. Since the start of the Iran war at the end of February, the rate was up nearly a ha...
US mortgage rates increased last week to an almost two-month high, weighing on home purchase activity. The contract rate on a 30-year mortgage rose 10 basis points to 6.56% in the week ended May 15, according to Mortgage Bankers Association data released Wednesday, just shy of the 6.57% reading at the end of March. Since the start of the Iran war at the end of February, the rate was up nearly a half percentage point through the latest week. An index of home-purchase applications fell 4.1%, the most since the week ended March 20. MBA’s refinancing index eased slightly. The yield on the 10-year Treasury note, which offers a guide to the direction of home-financing costs, has been rising as a jump in energy prices caused by the Middle East conflict contributes to inflation fears. On Tuesday, the yield jumped to the highest since January of last year. Mortgage News Daily, which updates home financing costs more frequently, put the 30-year fixed rate at 6.75% on Tuesday. Rising mortgage rates threaten to spoil budding optimism about a pickup in housing activity as the spring selling season gets underway. New-home sales in March were the strongest this year, while National Association of Realtors data showed April contract signings on previously owned homes reached a five-month high. Read More: US Pending Home Sales Increase for a Third Straight Month The MBA survey, which has been conducted weekly since 1990, uses responses from mortgage bankers, commercial banks and thrifts. The data cover more than 75% of all retail residential mortgage applications in the US.
This rip-roaring AI-powered bull market has already overcome a handful of potentially existential challenges — from the 2023 collapse of Silicon Valley Bank to last year’s tariff tantrum.
This rip-roaring AI-powered bull market has already overcome a handful of potentially existential challenges — from the 2023 collapse of Silicon Valley Bank to last year’s tariff tantrum.
BRANFORD, Conn., May 20, 2026 (GLOBE NEWSWIRE) -- Sachem Capital Corp. (NYSE American: SACH) (“Sachem” or the “Company”), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property, today announced its financial results for the quarter ended March 31, 2026. John Villano, CPA, Sachem’s Chief Execu...
BRANFORD, Conn., May 20, 2026 (GLOBE NEWSWIRE) -- Sachem Capital Corp. (NYSE American: SACH) (“Sachem” or the “Company”), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property, today announced its financial results for the quarter ended March 31, 2026. John Villano, CPA, Sachem’s Chief Executive Officer, commented, “During the first quarter, we remained focused on disciplined capital and liquidity management, continuing the strategic priorities established last year. We made meaningful progress resolving legacy loan issues and protecting invested capital, positioning the Company for improved operating performance and future growth. Subsequent to quarter end, we announced a transformational combination transaction with Industrial Realty Group, which will add significant industrial property lease-driven revenue while enhancing our ability to deliver creative capital solutions to real estate investors. We believe this combination will add meaningful scale and diversification to our asset base, positioning the Company to generate consistent and attractive risk-adjusted returns for shareholders over time.” Recent Development Contribution Agreement with Industrial Realty Group Global, LLC As previously announced, the Company and Industrial Realty Group (“IRG”), a private real estate development and investment firm specializing in the acquisition, development and management of commercial and industrial real estate throughout the United States, entered into a definitive contribution agreement under which IRG will contribute 98 industrial assets from its 200-asset portfolio owned by IRG and/or its partners to Sachem, and once completed, the combined company will operate as IRG Realty Trust, Inc. (“IRGT”). Upon closing, IRGT is expected to own 98 industrial properties with gross real estate asset value of $2.9 billion plus Sachem’s approximately $470 million of total as...
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) fully enrolled with topline dat...
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) fully enrolled with topline data expected in the second half of calendar year 2026 All other clinical development timelines remain on track for IMVT-1402, including potentially registrational studies in Graves’ disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren’s disease (SjD) Current cash balance provides runway to the potential launch of IMVT-1402 in GD Roivant will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to discuss these updates DURHAM, N.C., May 20, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported corporate updates and financial results for its fourth quarter and fiscal year ended March 31, 2026. Recent Highlights and Upcoming Milestones: The Company announced preliminary Week 16 (end of Period 1) results from the IMVT-1402 trial in D2T RA with ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8%, respectively, observed. Further updates on this program, as well as topline data from the fully enrolled proof-of-concept trial in CLE, are expected in the second half of calendar year 2026. Other clinical development timelines remain on track for IMVT-1402, including potentially registrational trials in GD, MG, CIDP, and SjD. Immunovant’s cash position provides runway to the potential launch of IMVT-1402 in GD. In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in GD and MG. In April 2026, we announced topline resu...
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) b...
IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA); Immunovant will provide further updates on this program in the second half of calendar year 2026 Brepocitinib granted Breakthrough Therapy Designation for the treatment of cutaneous sarcoidosis (CS) based on positive Phase 2 data; potentially registrational trial of brepocitinib in lichen planopilaris (LPP) enrolled its first subjects in March 2026 Commercial launch of brepocitinib in dermatomyositis (DM) is expected by the end of September 2026, and topline Phase 3 data for brepocitinib in non-infectious uveitis (NIU) is expected in the second half of calendar year 2026 IMVT-1402 proof-of-concept trial in cutaneous lupus erythematosus (CLE) is fully enrolled, with topline data expected in the second half of calendar year 2026; all other clinical development timelines remain on track Mosliciguat Phase 2 PHocus study in pulmonary hypertension associated with interstitial lung disease (PH-ILD) completed enrollment of 135 subjects within one year of first patient dosing, with topline data expected in the second half of calendar year 2026 $2.25 billion global settlement reached with Moderna, ending all pending U.S. and international patent-infringement litigation between Genevant Sciences GmbH (Genevant), Arbutus and Moderna; Moderna to pay Genevant and Arbutus $950 million in July 2026 and an additional $1.3 billion contingent upon resolution of Moderna’s Section 1498 appeal favorable to Genevant and Arbutus Roivant reported consolidated cash, cash equivalents and marketable securities of $4.3 billion as of March 31, 2026, supporting cash runway into profitability Roivant will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, May 20, 2026, to report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business...
Key First Quarter reported data points: Revenue of $12.2 million, -19.0% vs. Q1 2025 GAAP net income from continuing operations of $343 thousand vs. $254 thousand in Q1 2025 GAAP net income from continuing operations per fully diluted share of $0.006 vs. $0.005 in Q1 2025 Non-GAAP adjusted EBITDA of $441 thousand vs. $593 thousand in Q1 2025 BROADVIEW, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Innova...
Key First Quarter reported data points: Revenue of $12.2 million, -19.0% vs. Q1 2025 GAAP net income from continuing operations of $343 thousand vs. $254 thousand in Q1 2025 GAAP net income from continuing operations per fully diluted share of $0.006 vs. $0.005 in Q1 2025 Non-GAAP adjusted EBITDA of $441 thousand vs. $593 thousand in Q1 2025 BROADVIEW, Ill., May 20, 2026 (GLOBE NEWSWIRE) -- Innovative Food Holdings, Inc. (OTCQB: IVFH) (“IVFH,” the “Company,” “we,” “our” or “us”), a national seller of gourmet specialty foods to professional chefs, today reported financial results for the quarter ended March 31, 2026. For the first quarter of 2026, revenue was $12.2 million compared with $15.0 million in the prior-year period. The revenue decline reflected known transition-related and competitive headwinds across Digital Channels, National Distribution, and Local Distribution. These results primarily relate to ongoing marketplace transition activity within Digital Channels, competitive pressures within National Distribution, and customer attrition within Local Distribution. Despite the lower revenue base, the Company continued to make progress improving operational discipline and simplifying the business. Operating income increased to $351 thousand compared with $260 thousand in Q1 2025, while net income from continuing operations increased to $343 thousand compared with $254 thousand in the prior-year period. Adjusted EBITDA was $441 thousand for Q1 2026 compared with $593 thousand in Q1 2025. Selling, general and administrative expenses declined approximately $888 thousand year over year, net cash used in operating activities improved significantly to $234 thousand from an approximate outflow of $1 million in the same period last year, and the Company materially strengthened its balance sheet following the sale of its former Pennsylvania facility. Gary Schubert, Chief Executive Officer of IVFH, stated, “Q1 was not a revenue recovery quarter. Revenue remained under p...
SHANGHAI, China, May 20, 2026 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Net revenue increased by 23.6% year-over-year (“Y-o-Y...
SHANGHAI, China, May 20, 2026 (GLOBE NEWSWIRE) -- GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Highlights Net revenue increased by 23.6% year-over-year (“Y-o-Y”) to RMB3,367.1 million (US$488.1 million) in the first quarter of 2026 (1Q2025: RMB2,723.2 million). Net revenue excluding some one-time items was RMB2,938.0 million (US$425.9 million), an increase of 7.9% Y-o-Y. Net income increased by 247.1% Y-o-Y to RMB2,652.1 million (US$384.5 million) in the first quarter of 2026 (1Q2025: RMB764.1 million). Net income margin was 78.8% in the first quarter of 2026 (1Q2025: 28.1%). Adjusted EBITDA (non-GAAP) increased by 47.2% Y-o-Y to RMB1,948.7 million (US$282.5 million) in the first quarter of 2026 (1Q2025: RMB1,323.8 million). Adjusted EBITDA (non-GAAP) excluding some one-time items was RMB1,430.3 million (US$207.3 million), an increase of 8.0% Y-o-Y. See “Non-GAAP Disclosure” and “Reconciliations of GAAP and non-GAAP results” elsewhere in this earnings release. Adjusted EBITDA margin (non-GAAP) was 57.9% in the first quarter of 2026 (1Q2025: 48.6%). Adjusted EBITDA margin (non-GAAP) excluding some one-time items was 48.7%. First Quarter 2026 Operating Highlights Total area committed and pre-committed increased by 11.7% Y-o-Y to 725,485 sqm as of March 31, 2026 (March 31, 2025: 649,561 sqm). Area utilized increased by 12.7% Y-o-Y to 520,929 sqm as of March 31, 2026 (March 31, 2025: 462,423 sqm). Area in service increased by 10.4% Y-o-Y to 674,269 sqm as of March 31, 2026 (March 31, 2025: 610,685 sqm) Utilization rate (area utilized divided by area in service) was 77.3% as of March 31, 2026 (March 31, 2025: 75.7%). “We started 2026 with very strong sales,” said Mr. William Huang, Chairman and Chief Executive Officer of GDS. “During ...
SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: QuidelOrtho Corporation (PRNewsfoto/QuidelOrtho Corporation) William Blair 46th Annual Growth Stock Conference, Tuesday, June 2,...
SAN DIEGO, May 20, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of innovative in vitro diagnostics, announced today that members of its management team will participate in two upcoming investor conferences: QuidelOrtho Corporation (PRNewsfoto/QuidelOrtho Corporation) William Blair 46th Annual Growth Stock Conference, Tuesday, June 2, 2026 Members of QuidelOrtho's management team will participate in a presentation at 12:20 p.m. ET / 9:20 a.m. PT. Jefferies Global Healthcare Conference, Wednesday, June 3, 2026 Members of QuidelOrtho's management team will participate in a fireside chat at 8:10 a.m. ET / 5:10 a.m. PT. Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/. QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X. About QuidelOrtho Corporation With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care. Investor Contact: Juliet Cunningham Vice President, Investor Relations IR@QuidelOrtho.com Media Contact: Stephanie Kleewein Senior Corporate Communications and PR Manager media@QuidelOrtho.com Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-to-participate-in-upcoming-june-2026-investor-conferences-302777345.html
Four major artificial intelligence chatbots — OpenAI’s ChatGPT, Alphabet Inc.’s Google Gemini, Anthropic’s Claude and xAI’s Grok — are struggling to fairly and accurately answer questions about elections and geopolitics, according to a new study from Forum AI . Researchers asked the four chatbots more than 3,100 questions about a wide range of news topics, like politics, healthcare and foreign aff...
Four major artificial intelligence chatbots — OpenAI’s ChatGPT, Alphabet Inc.’s Google Gemini, Anthropic’s Claude and xAI’s Grok — are struggling to fairly and accurately answer questions about elections and geopolitics, according to a new study from Forum AI . Researchers asked the four chatbots more than 3,100 questions about a wide range of news topics, like politics, healthcare and foreign affairs. They found that the collective answers about elections, in particular, “failed on accuracy, bias, or source selection 90% of the time.” Nearly 36% of answers to questions about elections contained at least one factual error; Grok — the most egregious offender — returned an error nearly 52% of the time. When ChatGPT, Claude and Gemini returned biased answers, they aligned with the political left, and Grok primarily tilted in favor of the political right. All four models also routinely relied on foreign, state-owned media as reliable sources of information. In 35% of responses to foreign policy questions, the chatbots cited state-controlled sources such as China’s Global Times or CGTN, or Russia’s RT. ChatGPT and Grok were the worst offenders, citing state-owned media 51% and 44% of the time, respectively. In many of the cases, the chatbots returned biased or inaccurate information with a confidence that was even more misleading, the study found. “The most professional-looking answers, backed by strongest-looking citations, were also the most likely to contain buried factual errors,” Forum said Wednesday in a statement, calling it one of the study’s “sharpest findings.” Chatbots often struggle with news accuracy, especially on breaking stories where there is limited information available online. AI models that power chatbots are often trained on wide swaths of data found on the open web, a notoriously untrustworthy source of facts and nuance. Campbell Brown , chief executive officer of Forum AI and a former head of news partnerships at Meta Platforms Inc., said she is p...
00:00 Speaker A So let's talk about some non-AI picks. First up is Netflix. 00:02 Speaker B After the Warner Brothers potential bid which they walked away from, the stock pulled back, there was some worries around that. We're now back to the core story which is a combination of subscriber growth, a combination of the pricing action where you have the ability to have a lower price product with a hi...
00:00 Speaker A So let's talk about some non-AI picks. First up is Netflix. 00:02 Speaker B After the Warner Brothers potential bid which they walked away from, the stock pulled back, there was some worries around that. We're now back to the core story which is a combination of subscriber growth, a combination of the pricing action where you have the ability to have a lower price product with a higher margin for the company. Remember the advertise support business they have. Then the other part is the company is also doing a good job of experimenting its its its actual product offer, getting to things like some live sports entertainment, also live podcasting. The key thing we think of sourcing a lot of content from international and bringing it here. The nice thing is a lot of content outside the US is a lot cheaper to bring in. and they're really the only streamer that can do that. We continue to see this as a very nice top line compounder along with very good earnings potential and now obviously free cash for growth as well. 00:46 Speaker A Let's say the consumer weakens. What would that mean for Netflix? 00:49 Speaker B They've kind of thought ahead of this. It used to be it was the 1999 or $20 a month. You do have the ad supported tier which is half that price. And this is very attractive because it's also growing the potential user base. So I think they're somewhat recession proof there because for that quality of spending, you're probably going to still be spending on watching Netflix at 10 bucks. 01:07 Speaker A Here's another name. uh Games Workshop. I'm not familiar with this one, so walk me through this business. 01:13 Speaker B So this is a $10 billion market cap company, about a billion dollars of revenues, growing consistently sort of like double digit earnings. Their biggest thing is a board game called Warhammer 40K. It's a table top game. It's estimated there's about 4 million people who've played this game globally, about half a million who spend an...
Key Points Eagle Materials' diversified business is supported by infrastructure and data center demand. Outperformance in the company's fiscal 2026 points to continued strength in fiscal 2027. Capital returns are central to this investment, with share buybacks aggressively reducing the count. Eagle Materials (NASDAQ: EXP) is not exactly an AI play, as it has no exposure to the tech market beyond i...
Key Points Eagle Materials' diversified business is supported by infrastructure and data center demand. Outperformance in the company's fiscal 2026 points to continued strength in fiscal 2027. Capital returns are central to this investment, with share buybacks aggressively reducing the count. Eagle Materials (NASDAQ: EXP) is not exactly an AI play, as it has no exposure to the tech market beyond its own investment in operational quality. However, as the nation's 7th-largest producer of cement and concrete, and the largest U.S.-owned manufacturer of gypsum wallboard, it is very well positioned for the AI data center buildout. Datacenters are not only on track to double and triple in number over the coming years, but their size and scale are increasing. They rely heavily on concrete, cement, and gypsum wallboard for structural support in the first two cases, and fire safety, temperature, and humidity control across the board. Domestic cement volume demand alone is expected to double over the coming years, topping 2 million metric tonnes annually, while tepid housing demand for wallboard is expected to be offset by datacenters. The takeaway for investors is that Eagle Materials, a high-quality, cash-flow-producing, capital-returning machine, is positioned to grow. More importantly, it has expansion projects underway at its core manufacturing facilities, aiming to capture market demand while improving operational metrics. The likely outcome is that this company not only sustains growth in the upcoming years but also accelerates while widening margins. As it stands, analysts expect only about 10% revenue growth over the next two years, setting the stage for outperformance and a bullish revision cycle that may persist for years. Eagle Materials Outperforms as Cement Demand Ramps Eagle Materials had a solid fiscal Q4, with strength in the Heavy Materials offsetting weakness in Light Construction Materials. The $479.1 million in net revenue outperformed MarketBeat’s reporte...
Enterprise software is undergoing a major transformation driven by AI, unleashing unprecedented market expansion for platforms that are adopting autonomous architecture. A shift is underway, splitting the legacy Software-as-a-Service (SaaS) ecosystem into clear winners and losers, effectively ending the era of blanket multiples for cloud software. Investors are now tasked with identifying the comp...
Enterprise software is undergoing a major transformation driven by AI, unleashing unprecedented market expansion for platforms that are adopting autonomous architecture. A shift is underway, splitting the legacy Software-as-a-Service (SaaS) ecosystem into clear winners and losers, effectively ending the era of blanket multiples for cloud software. Investors are now tasked with identifying the companies building this new economy, and old advantages are rapidly becoming new liabilities. Two sector titans, ServiceNow NYSE: NOW and Salesforce NYSE: CRM, offer a compelling view into this divergence. ServiceNow is capturing immediate structural premiums by establishing an enterprise-wide AI governance backbone. Salesforce, facing pressure on its legacy model, is deploying an additional $25 billion to its capital restructuring program and utilizing a targeted $300 million commitment to Anthropic to turbocharge its ecosystem into a dynamic, AI-native CRM powerhouse. This difference in strategy creates a unique environment for investors, highlighting two distinct paths to capitalizing on the AI revolution. Get ServiceNow alerts: Sign Up ServiceNow's AI Moat: Building the Enterprise Brain ServiceNow Today NOW ServiceNow $101.44 -0.39 (-0.38%) 52-Week Range $81.24 ▼ $211.48 P/E Ratio 60.36 Price Target $141.89 Add to Watchlist ServiceNow appears poised to benefit from the strategic pivot from a workflow tool to a core enterprise intelligence engine. The market is rewarding this shift, with ServiceNow's share price rallying after Bank of America initiated coverage and set a $130 price target. The bank flagged ServiceNow as a major beneficiary of agentic AI, with its business model offering some insulation from the disruption hitting traditional software. The firm's forward price-to-earnings (P/E) ratio is elevated at 44, which reflects investor confidence that this advantage will drive significant earnings growth. ServiceNow's Pivot to AI Rulemaker The recent Knowledge 2026 con...
Walleye Partners LLC bought a new stake in shares of Apple Inc. (NASDAQ:AAPL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,507 shares of the iPhone maker's stock, valued at approximately $682,000. Apple accounts for 0.8% of Walleye Partners LLC's holdings, making the stock its 20th biggest holding. Ot...
Walleye Partners LLC bought a new stake in shares of Apple Inc. (NASDAQ:AAPL - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,507 shares of the iPhone maker's stock, valued at approximately $682,000. Apple accounts for 0.8% of Walleye Partners LLC's holdings, making the stock its 20th biggest holding. Other large investors also recently added to or reduced their stakes in the company. Reyes Financial Architecture Inc. boosted its position in shares of Apple by 0.4% in the third quarter. Reyes Financial Architecture Inc. now owns 9,898 shares of the iPhone maker's stock worth $2,520,000 after purchasing an additional 37 shares during the period. WESPAC Advisors LLC boosted its position in shares of Apple by 0.3% in the fourth quarter. WESPAC Advisors LLC now owns 12,326 shares of the iPhone maker's stock worth $3,351,000 after purchasing an additional 39 shares during the period. American Alpha Advisors LLC boosted its position in shares of Apple by 3.7% in the third quarter. American Alpha Advisors LLC now owns 1,151 shares of the iPhone maker's stock worth $293,000 after purchasing an additional 41 shares during the period. Seven Springs Wealth Group LLC boosted its position in shares of Apple by 0.3% in the third quarter. Seven Springs Wealth Group LLC now owns 15,451 shares of the iPhone maker's stock worth $3,934,000 after purchasing an additional 42 shares during the period. Finally, Avant Capital LLC boosted its position in shares of Apple by 0.9% in the third quarter. Avant Capital LLC now owns 4,814 shares of the iPhone maker's stock worth $1,226,000 after purchasing an additional 43 shares during the period. 67.73% of the stock is currently owned by institutional investors. Get Apple alerts: Sign Up Analyst Upgrades and Downgrades A number of research firms have weighed in on AAPL. Scotiabank set a $330.00 price target on shares of Apple in a research report on Mo...
Verdence Capital Advisors LLC reduced its stake in shares of NVIDIA Corporation (NASDAQ:NVDA - Free Report) by 7.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 91,033 shares of the computer hardware maker's stock after selling 7,534 shares during the period. NVIDIA comprises 1.0% of Verdence Capital Advisors LLC's investment ...
Verdence Capital Advisors LLC reduced its stake in shares of NVIDIA Corporation (NASDAQ:NVDA - Free Report) by 7.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 91,033 shares of the computer hardware maker's stock after selling 7,534 shares during the period. NVIDIA comprises 1.0% of Verdence Capital Advisors LLC's investment portfolio, making the stock its 20th biggest position. Verdence Capital Advisors LLC's holdings in NVIDIA were worth $16,978,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Longfellow Investment Management Co. LLC lifted its stake in shares of NVIDIA by 47.9% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 207 shares of the computer hardware maker's stock valued at $33,000 after buying an additional 67 shares in the last quarter. Spurstone Advisory Services LLC purchased a new stake in shares of NVIDIA during the 2nd quarter valued at approximately $40,000. Sellwood Investment Partners LLC purchased a new stake in shares of NVIDIA during the 3rd quarter valued at approximately $50,000. Networth Advisors LLC purchased a new stake in shares of NVIDIA during the 4th quarter valued at approximately $51,000. Finally, EDENTREE ASSET MANAGEMENT Ltd purchased a new stake in shares of NVIDIA during the 2nd quarter valued at approximately $54,000. 65.27% of the stock is owned by institutional investors. Get NVIDIA alerts: Sign Up NVIDIA Price Performance Shares of NASDAQ:NVDA opened at $220.61 on Wednesday. The company's fifty day moving average price is $194.00 and its 200-day moving average price is $188.61. The firm has a market capitalization of $5.34 trillion, a price-to-earnings ratio of 45.02, a PEG ratio of 0.69 and a beta of 2.25. NVIDIA Corporation has a one year low of $129.16 and a one year high of $236.54...